The pharmaceutical industry is entering a new era where innovation is no longer driven by individual organisations alone. From drug discovery and clinical research to manufacturing, regulatory compliance, digital transformation, and global commercialisation, success increasingly depends on strategic partnerships that combine expertise, technology, and shared ambition.
The Global Pharma Partnering Summit 2026 serves as a…
Shots:
Repligen has entered into a definitive agreement to acquire BioLife
Repligen will acquire BioLife for an enterprise value of ~$1.5B, with BioLife stockholders receiving $11.25 per share in cash plus 0.1442 Repligen shares, representing total consideration of $31/share, comprising 64% stock & 36% cash
Acquisition is expected to fast-track Repligen’s leadership & customer solutions…
The Pharmaceutical Packaging Summit 2026 will bring together senior pharmaceutical packaging leaders and innovative solution providers for a high value, invitation only forum. The event will take place 5 to 6 October 2026 at the Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA, USA, connecting executives with strategies shaping the future of…
Shots:
Mabwell has entered a licensing and commercialization agreement with a Malaysian partner for its denosumab biosimilars, Mailishu (biosimilar, Prolia) and Maiweijian (biosimilar, Xgeva)
As per the deal, the partner will handle registration and commercialization in Malaysia
While Mabwell will oversee the development, manufacturing, and supply of the products
Ref: Mabwell | Image: Mabwell | Press Release
Related News: Mabwell Initiates P-III Trial for 9MW2821 in TNBC…
Shots:
Biocon Biologics secured full global rights to Hulio (Adalimumab), a biosimilar of adalimumab, from Fujifilm Kyowa Kirin Biologics
As per the agreement, Biocon Biologics will take full responsibility for manufacturing, commercialization, and further development, while FKB will support development, offset certain development costs, and receive technology license fees and royalties for a specified tenure
Biocon Biologics…
Shots:
The biopharma industry faces several challenges, including digital transformation, regulatory compliance, and managing large volumes of data
Intelligent automation plays a vital role in drug discovery, clinical trials, manufacturing, and commercialization, helping optimize operations and better meet customer needs
Astrix CEO Dale Curtis Jr. discusses the role of AI and machine learning in global…
Shots:
Backed with an evergreen investment strategy, Invus makes investments across several company stages ranging from early growth to turnarounds
In 2023, Invus participated in 6 investment rounds in around 29 companies focusing on biopharma, manufacturing & services, and devices
For a curated report on a specific investor or venture capital, reach out to us…
Shots:
In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and Healthcare
In 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…
Shots:
The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industry
In February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative Colitis
PharmaShots has compiled a list of a total…
Shots:
Know Your Investor is an earnest effort from PharmaShots to acquaint our readers with leading Investors and venture capital firms in the healthcare industry
Founded in 1969, F-Prime Capital Partners is a subsidiary of Fidelity Investments and primarily invests in healthcare and technology
A total of 40 investments were closed by F-Prime in 2023,…

